# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Data presented at EHA showed anti-tumor activity for the company's investigational PROTAC BCL6 degrader, ARV-393, in precli...
HC Wainwright & Co. analyst Andrew Fein reiterates Arvinas (NASDAQ:ARVN) with a Buy and maintains $87 price target.
After six months of additional follow-up, these data are consistent with data presented at the San Antonio Breast Cancer Sympos...
Wells Fargo analyst Derek Archila maintains Arvinas (NASDAQ:ARVN) with a Overweight and lowers the price target from $63 to ...
Wedbush analyst Robert Driscoll reiterates Arvinas (NASDAQ:ARVN) with a Outperform and maintains $57 price target.